An Epidemiological Study on the Status of Hydatid cyst in Surgical Patients in Golestan Hospital of Ahwaz During 2002-2011

Saki, Jasem; Khodkar, Iman; Hardani Pasand, Leila; Nazari, Iraj

doi:10.30699/ijmm.12.6.442

year 12, Issue 6 (January - February 2019) Iran J Med Microbiol 2019, 12(6): 442-446 | Back to browse issues page

‎ 10.30699/ijmm.12.6.442

Mendeley

Zotero

RefWorks

Saki J, Khodkar I, Hardani Pasand L, Nazari I. An Epidemiological Study on the Status of Hydatid cyst in Surgical Patients in Golestan Hospital of Ahwaz During 2002-2011. Iran J Med Microbiol 2019; 12 (6) :442-446
URL: http://ijmm.ir/article-1-815-en.html

An Epidemiological Study on the Status of Hydatid cyst in Surgical Patients in Golestan Hospital of Ahwaz During 2002-2011

Jasem Saki¹

, Iman Khodkar¹

, Leila Hardani Pasand

², Iraj Nazari³

1- Department of Medical Parasitology,School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2- Department of Medical Parasitology,School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran , hardani2013@gmail.com
3- Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract: (5689 Views)

Background and Aims: Hydatidosis is one of the most important zoonotic parasitic diseases. Hydatidosis is endemic in Iran and is the cause of hospitalization of almost 1% of patients in surgical wards. The purpose of this study is to examine the epidemiologic status of hydatid cyst in patients undergoing surgery in Golestan hospital of Ahvaz during 2002-2011 using archived files of the patients.
Materials and Methods: This research is a cross-sectional study. During the mentioned period, 2002 until 2011, 55 patients in Ahvaz Golestan hospital have undergone hydatid cyst surgery and the information in the patients' files were examined by referring to the relevant archives in the mentioned hospital.
Results & Conclusion: Among the 55 patients studied, 37 (67.3%) were female and 18 patients (32.7%) were male. The highest incidence rate was found in liver with 47 cases (85.5%), followed by lung with 5 cases (9%). Considering the results, the highest prevalence rate was found among urban residents (n=33 ,60%) whilst 22 cases(40%) belonged to the rural residents. The results of this study indicate that the occurrence of the disease was significant in Khuzestan province during the mentioned period which reflects the necessity of more comprehensive and updated studies.

Keywords: Hydatidosis, Hydatid cyst surgery, Ahwaz Golestan Hospital, Epidemiology

Full-Text [PDF 735 kb] (1754 Downloads)

Type of Study: Original Research Article | Subject: Medical Parasitology
Received: 2018/02/10 | Accepted: 2019/01/7 | ePublished: 2019/03/29

References

1. Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: hepatoblastoma. Oncologist. AlphaMed Press; 2000;5:445-53. [DOI:10.1634/theoncologist.5-6-445] [PMID]

2. G.Y. Hung, L.Y. Lin, T.Y. Yu, C.Y. Lee, H.J. Yen, J.L. Horng Hepatoblastoma incidence in Taiwan: a population-based study, J Chin Med Assoc, 81 (2018), 541-547 [DOI:10.1016/j.jcma.2017.11.012] [PMID]

3. Reynolds P, Urayama KY, Von Behren J, Feusner J. Birth characteristics and hepatoblastoma risk in young children. Cancer 2004;100:1070-6. [DOI:10.1002/cncr.20061] [PMID]

4. L.G. Spector, J. Birch. The epidemiology of hepatoblastoma, Pediatric Blood Cancer, 59 (2012), 776-779 [DOI:10.1002/pbc.24215] [PMID]

5. Otten J, Smets R, De Jager R, Gerard A, Maurus R. Hepatoblastoma in an infant after contraceptive intake during pregnancy. N Engl J Med. 1977; 297: 222. [DOI:10.1056/NEJM197707282970417] [PMID]

6. Perilongo G, Shafford E, Maibach R, Aronson D, Brugie'res L, Brock P, et al. Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology SIOPEL 2. Eur J Cancer 2004; 40:411e21.

7. Aronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Perilongo G, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: Results from the international society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol. 2005;23:1245-52. [DOI:10.1200/JCO.2005.07.145] [PMID]

8. Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville de Goyet J, Gauthier F, et al. International Childhood Liver Tumor Strategy Group 2005 PRETEXT: A revised staging system for primary malignant liver tumors of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37:123-32. [DOI:10.1007/s00247-006-0361-5] [PMID] [PMCID]

9. Shanmugam N, Scott JX, Kumar V, Vij M, Ramachandran P, Narasimhan G, et al. Multidisciplinary management of hepatoblastoma in children: Experience from a developing country. Pediatric Blood Cancer 2017;64:e26249. [DOI:10.1002/pbc.26249] [PMID]

10. P. Czauderna, B. Haeberle, E. Hiyama, A. Rangaswami, M. Krailo, R. Maibach, et al. The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer, 52 (2016), 92-101 [DOI:10.1016/j.jped.2015.12.001]

11. Ninane J, Perilongo G, Stalens JP, Guglielmi M, Otte JB, Mancini A. Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: A SIOP pilot study. Med Pediatr Oncol. 1991;19:199-203. [DOI:10.1002/mpo.2950190310] [PMID]

12. Ortega JA, Kralio MD, Haas JE, King DR, Ablin AR, Quinn JJ, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin: A report from the Children's Cancer Study Group. J Clin Oncol. 1991;9:2167-76 [DOI:10.1200/JCO.1991.9.12.2167] [PMID]

13. Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: A pediatric oncology group study. J Clin Oncol. 1993;11:96-9. [DOI:10.1200/JCO.1993.11.1.96] [PMID]

14. Weinblatt ME, Siegel SE, Siegel MM, Stanley P, Weitzman JJ. Preoperative chemotherapy for unresectable primary hepatic malignancies in children. Cancer. 1982;50:1061-4. https://doi.org/10.1002/1097-0142(19820915)50:6<1061::AID-CNCR2820500607>3.0.CO;2-Q [DOI:10.1002/1097-0142(19820915)50:63.0.CO;2-Q] [PMID]

15. Filler RM, Ehrlich PF, Greenberg ML, Babyn PS. Preoperative chemotherapy in hepatoblastoma. Surgery. 1991;110:591-7

16. Von Schweinitz D, Byrd DJ, Hecker H, Weinel P, Bode U, Bürger D, et al. Efficiency and toxicity of ifosfamide, cisplatin, and doxorubicin in the treatment of childhood hepatoblastoma. Study committee of the Cooperative Paediatric Liver Tumor Study HB89 of the German Society of Paediatric Oncology and Haematology. Eur J Cancer.1997;33:1243-9. [DOI:10.1016/S0959-8049(97)00095-6] [PMID]

17. Kalifa C, Lemerle J, Caillaud JM. Resectability of childhood hepatoblastoma is improved by primary chemotherapy. Proc Am Soc Clin Oncol. 1984:c308.

18. G. Perilongo, E. Shafford, R. Maibach, D. Aronson, L. Brugières, P. Brock, M. Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2,European Journal of Cancer, Volume 40, Issue 3, 2004,411-421. [DOI:10.1016/j.ejca.2003.06.003] [PMID]

19. Dietrich von Schweinitz, Hepatoblastoma: recent developments in research and treatment, Seminars in Paediatric Surgery, Volume 21, Issue 1,2012,21-30. [DOI:10.1053/j.sempedsurg.2011.10.011] [PMID]

20. J. Zsiros, L. Brugieres, P. Brock, D. Roebuck, R. Maibach, A. Zimmermann, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol, 14 (2013), 834-842

21. Finegold MJ. Hepatic Tumors in Childhood. In: Russo P RE, Piccoli D, eds. Pathology of Paediatric Gastrointestinal and Liver Disease. New York, NY: Springer-Verlag; 2004:300-346. [DOI:10.1007/978-1-4419-9066-2_13]

22. FT Bosman, F Carneiro, RH Hruban et al. eds. WHO classification of tumours of the digestive system, 5th ed. Lyon: International Agency for Research on Cancer, 2019; 240-244

23. S. Cairo, C. Armengol, A. De Reyniès, Y. Wei, E. Thomas, C.A. Renard, et al. Hepatic stem-like phenotype and interplay of Wnt/β-catenin and Myc signaling in aggressive childhood liver cancer Cancer Cell, 14 (2008), 471-484 [DOI:10.1016/j.ccr.2008.11.002] [PMID]

24. J.F. Wu, C.H. Lee, H.L. Chen, Y.H. Ni, H.Y. Hsu, J.C. Sheu, etal. Copy-number variations in hepatoblastoma associated with unique clinical features. Hepatol Int, 7 (2013),208-214 [DOI:10.1007/s12072-012-9350-y] [PMID]

25. Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pre-treatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol. 2005;23(6):1245-1252. [DOI:10.1200/JCO.2005.07.145] [PMID]

26. Rebecka L Meyers, Rudolf Maibach, Eiso Hiyama, Beate Häberle, Mark Krailo. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration, The Lancet Oncology,Volume 18, Issue 1,2017,122-131. [DOI:10.1016/S1470-2045(16)30598-8] [PMID]

27. Rowland JM: Hepatoblastoma: assessment of criteria for histologic classification. Med Paediatric Oncol. 2002; 39(5): 478-83. [DOI:10.1002/mpo.10171] [PMID]

28. R.L. Meyers, J.R. Rowland, M. Krailo, Z. Chen, H.M. Katzenstein, M.H. Malogolowkin. Predictive power of pre-treatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group Pediatr Blood Cancer, 53 (2009), pp. 1016-1022 [DOI:10.1002/pbc.22088] [PMID] [PMCID]

29. J. Fuchs, J. Rydzynski, D. Von Schweinitz, U. Bode, H. Hecker, P. Weinel, et al. Pre-treatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Paediatric Liver Tumor Study HB 94. Cancer, 95 (2002), 172-182.

30. Wei-Yun Hsu ,Hsiu-Hao Chang , Meng-Yao Lu , Yung-Li Yang. Clinical risk stratification of children with SIOPEL high-risk hepatoblastoma in Taiwan, Paediatrics and neonatology 2020;61: 393-398. [DOI:10.1016/j.pedneo.2020.03.012] [PMID]

31. Archana B, Thanka J,Sneha LM, Scott JJX, Arunan M, Agarwal P. Clinicopathological profile of hepatoblastoma: An experience from a tertiary care centre in India. Indian J Pathol Microbiol 2019;62: 556-560 [DOI:10.4103/IJPM.IJPM_200_19] [PMID]